New pediatric cancer marker, new hope for a treatment target
Researchers have newly identified a universal, essential biomarker for the childhood cancer neuroblastoma – and a potential new target for treatment.
Neuroblastoma accounts for 15% of all pediatric cancer deaths and is the most common source of childhood tumors outside of brain cancer. The disease develops in early nerve tissue, usually in and around the adrenal glands, and typically affects children under age five. High-risk cases have a five-year survival rate of just 50%.
Led by UC San Francisco, researchers suspected the oncoprotein AF1q, which is known to play a role in leukemia and solid tumor progression, might be important in tumors of neural origin ...








